Table 5 Prognostic factors of 28-day mortality in FN patients by Cox regression univariate analysis
Variables | Mortality group | Survival group | HR (95% CI) | P-value |
|---|---|---|---|---|
N = 29 | N = 278 | |||
Age, mean ± SD, years | 41.6 ± 15.0 | 40.6 ± 14.1 | 1.00 (0.98–1.03) | 0.62 |
Clinical comorbidity (%) | 6 (20.6) | 70 (25.1) | 0.82 (0.33–2.01) | 0.66 |
Type of neoplastic disease | 24 (82.8) | 218 (78.4) | 1.20 (0.45–3.15) | 0.70 |
- Haematological (%) | 5 (17.2) | 60 (21.6) | – | – |
- Solid tumour (%) | ||||
Relapsing underlying disease status (%) | 23 (79.3) | 132 (47.4) | 4.30 (1.75–10.58) | 0.001 |
Chemotherapy regimens | 9 (31.0) | 155 (55.8) | 0.39 (0.17–0.86) | 0.02 |
- High-dose (%) | 20 (69.0) | 123 (44.2) | – | - |
- Standard-dose (%) | ||||
Median ANC at the time of the diagnosis of FN (IQR), cells/mm3 | 130 (40–300) | 130 (50–310) | 1.00 (0.99–1.00) | 0.37 |
ANC < 100 cells/mm3 at the time of the diagnosis of FN | 16 (55.1) | 114 (41.0) | 1.68 (0.80–3.49) | 0.16 |
Duration of neutropaenia, median (IQR), days | 8 (4–20) | 9 (6–17) | 0.97 (0.93–1.01) | 0.23 |
Documented BSI (%) | 20 (69.0) | 95 (34.2) | 3.91 (1.78–8.60) | 0.001 |
BSI involving Gram-positive MDR bacteria (%) | 2 (6.9) | 25 (9.0) | 0.74 (0.17–3.12) | 0.68 |
BSI involving Gram-negative MDR bacteria (%) | 3 (10.3) | 9 (3.2) | 2.70 (0.81–8.94) | 0.10 |
High-risk MASCC score (%) | 18 (62.1) | 65 (23.4) | 5.03 (2.37–10.65) | <0.001 |
Hypotension at the time of diagnosis of FN (%) | 9 (31.0) | 22 (7.9) | 4.72 (2.14–10.37) | <0.001 |
Time to antibiotic therapy >1 h | 15 (51.7) | 62 (22.3) | 4.13 (1.85–9.20) | 0.001 |
In vitro sensitivity of blood isolates to initial antibiotic treatment administered (%) | 22 (75.8) | 246 (88.4) | 0.47 (0.20–1.10) | 0.08 |
ASP adherence (%) | 6 (20.7) | 156 (56.1) | 0.21 (0.08–0.53) | 0.001 |